ReviewJACC. Cardiovascular interventions2011
Emerging genomic applications in coronary artery disease.
Review in JACC. Cardiovascular interventions, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Pooled it
- APOE gene polymorphism and risk of coronary stenosis in Pakistani population.BioMed research international · 2015Trial
- Article
- Review
- Updated perspectives on vascular cell specification and pluripotent stem cell-derived vascular organoids for studying vasculopathies.Cardiovascular research · 2022Review
- Lrp1 Regulation of Pulmonary Function. Follow-Up of Human GWAS in Mice.American journal of respiratory cell and molecular biology · 2021Article
- High-Fat Diet and Alcohol Intake Promotes Inflammation and Impairs Skin Wound Healing in Wistar Rats.Mediators of inflammation · 2018Article
- Implementing genomics and pharmacogenomics in the clinic: The National Human Genome Research Institute's genomic medicine portfolio.Atherosclerosis · 2016Review
- Relationship between CYP17A1 genetic polymorphism and coronary artery disease in a Chinese Han population.Lipids in health and disease · 2015Article
- The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment.Journal of the American College of Cardiology · 2015Review
- Risk-Association of DNMT1 Gene Polymorphisms with Coronary Artery Disease in Chinese Han Population.International journal of molecular sciences · 2014Article
- Diplotypes of CYP2C9 gene is associated with coronary artery disease in the Xinjiang Han population for women in China.Lipids in health and disease · 2014Article
- Cancer genomics and inherited risk.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- A novel major histocompatibility complex locus confers the risk of premature coronary artery disease in a Chinese Han population.Molecular biology reports · 2013Article
- Next generation sequencing in cardiovascular diseases.World journal of cardiology · 2012Article
- Cardiovascular risk.British journal of clinical pharmacology · 2012Review
- Advancing cardiovascular research.Chest · 2012Review
- Genomics in cardiovascular diseases: analysis of the importance of the toll-like receptor signaling pathway.International journal of general medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Over the last 4 years, an unprecedented number of studies illuminating the genomic underpinnings of common "polygenic" diseases including coronary artery disease have been published. Notably, these studies have established numerous deoxyribonucleic acid (DNA) variants within or near chromosome 9p21.3, the LPA, CXADR, and APOE genes, to name a few, as key coronary artery disease and sudden cardiac death susceptibility markers. Most importantly, many of these DNA variants confer over a 2-fold increase in risk for coronary artery disease, myocardial infarction, and ventricular fibrillation. Additionally, loss-of-function variants in the hepatic cytochrome 2C19 system have now been found to be the predominant genetic mediators of clopidogrel antiplatelet response, with variant carriers having a >3-fold increase in risk for stent thrombosis. In the near future, many additional rare polymorphisms, structural variants, and tissue-specific epigenetic features of the human genome including DNA methylation, histone modifications, and chromatin state will emerge as significant contributors to disease pathogenesis and drug response. In aggregate, these findings will have the potential to radically change the practice of cardiovascular medicine. However, only the individual clinician can ultimately enable the translation of these important discoveries to systematic implementation in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.